{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:57:54Z","timestamp":1761541074681},"reference-count":19,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2012,2,15]],"date-time":"2012-02-15T00:00:00Z","timestamp":1329264000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objectives:\u2002<\/jats:bold> Current methods in assessing von Willebrand factor (VWF) ristocetin cofactor activity for Von Willebrand\u2019s disease (VWD) diagnosis include platelet agglutination by aggregometer or macroscopic slide examination, which are both time\u2010consuming with suboptimal interassay and intra\u2010assay variation. The purpose of this study is to establish a sensitive assay to detect VWF:RCo activity and evaluate its performance in VWD diagnosis.<\/jats:p><jats:p><jats:bold>Methods:\u2002<\/jats:bold> We have established a sensitive VWF:RCo\u2013ELISA method using a monoclonal antibody, SZ\u2010151, to immobilize the recombinant fragment of platelet glycoprotein Ib (rfGPIb<jats:italic>\u03b1<\/jats:italic>). VWF was captured by rfGPIb<jats:italic>\u03b1<\/jats:italic> in the presence of ristocetin, and then detected by HRP\u2010conjugated rabbit anti\u2010human VWF IgG. We tested the VWF:RCo level by this VWF:RCo\u2013ELISA in 25 patients with different types of VWD and 36 healthy donors, and compared this method to a previously reported ELISA using 2D4 coating antibody.<\/jats:p><jats:p><jats:bold>Results:\u2002<\/jats:bold> The sensitivity of VWF:RCo\u2013ELISA was greatly improved with this assay (0.008\u2003IU\/dL compared to 0.031\u2003IU\/dL by 2D4 antibody). The interassay and intra\u2010assay coefficient variation were 8% and 12%, respectively. The mean values (ranges) of VWF:RCo in patients with type 1, type 2A, type 2B, type 2M, and type 3 of VWD and control group are 31.8 (22.3\u201356.9), 4.8 (0.6\u201311.8), 8.6 (1.6\u201319.7), 3.9 (1.0\u20136.8), 1.0 (0.5\u20131.6), and 91.5 (47.3\u2013169.2) IU\/dL, respectively. The corresponding ratios (ranges) of VWF:RCo<jats:bold>\/<\/jats:bold>VWF:Ag are 0.83 (0.70\u20131.16), 0.27 (0.08\u20130.58), 0.31 (0.15\u20130.40), 0.18 (0.14\u20130.21), 0.52 (0.13\u20131.19), and 0.92 (0.62\u20131.26).<\/jats:p><jats:p><jats:bold>Conclusion:\u2002<\/jats:bold> The VWF:RCo\u2013ELISA using monoclonal anti\u2010rfGPIb<jats:italic>\u03b1<\/jats:italic> antibody SZ\u2010151 showed improved sensitivity and reliability in detecting VWF:RCo activity, and its clinical application would facilitate the diagnosis and classification of VWD.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2012.01760.x","type":"journal-article","created":{"date-parts":[[2012,1,23]],"date-time":"2012-01-23T12:49:50Z","timestamp":1327322990000},"page":"439-445","source":"Crossref","is-referenced-by-count":9,"title":["Development of an ELISA method for testing VWF ristocetin cofactor activity with improved sensitivity and reliability in the diagnosis of von Willebrand disease"],"prefix":"10.1111","volume":"88","author":[{"given":"Yiming","family":"Zhao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shundong","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianfeng","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziqian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Changgeng","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,2,15]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.2.454.454"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-10-165621"},{"key":"e_1_2_7_4_2","doi-asserted-by":"crossref","first-page":"8149","DOI":"10.1016\/S0021-9258(18)92954-6","article-title":"Dimeric ristocetin flocculates proteins, binds to platelets, and mediates von Willebrand factor\u2010dependent agglutination of platelets","volume":"266","author":"Scott JP","year":"1991","journal-title":"J Biol Chem"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1642471"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613992"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-947859"},{"key":"e_1_2_7_8_2","first-page":"94","article-title":"von Willebrand\u2019s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment","volume":"88","author":"Castaman G","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2002.00672.x"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1651343"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(75)90074-2"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613765"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2006.02146.x"},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1182\/blood.V69.2.570.570","article-title":"A murine antiglycoprotein Ib complex monoclonal antibody, SZ 2, inhibits platelet aggregation induced by both ristocetin and collagen","volume":"69","author":"Ruan CG","year":"1987","journal-title":"Blood"},{"key":"e_1_2_7_15_2","first-page":"650","article-title":"[Development, identification and function assay of monoclonal antibody against platelet membrane glycoprotein Ib]","volume":"27","author":"Gu Y","year":"2011","journal-title":"Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi"},{"key":"e_1_2_7_16_2","first-page":"547","article-title":"[Studies on monoclonal antibodies to human von Willebrand factor]","volume":"25","author":"Ruan CG","year":"1986","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2009.11.167"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02444.x"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2007.01643.x"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2010.02296.x"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2012.01760.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2012.01760.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T05:43:00Z","timestamp":1698730980000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2012.01760.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,15]]},"references-count":19,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1111\/j.1600-0609.2012.01760.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2012.01760.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,15]]}}}